vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 10.3%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
AMSF vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $75.5M |
| Net Profit | $8.1M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 10.2% | — |
| Revenue YoY | 10.3% | 27.7% |
| Net Profit YoY | -9.0% | — |
| EPS (diluted) | $0.43 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $75.5M | ||
| Q3 25 | $82.0M | $54.5M | ||
| Q2 25 | $81.1M | $52.4M | ||
| Q1 25 | $72.6M | $46.0M | ||
| Q4 24 | $74.0M | $59.1M | ||
| Q3 24 | $78.7M | $80.5M | ||
| Q2 24 | $75.8M | $47.1M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $13.8M | $8.8M | ||
| Q2 25 | $14.0M | $5.9M | ||
| Q1 25 | $8.9M | $3.0M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | $20.3M | ||
| Q2 24 | $11.0M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 22.7% | ||
| Q3 25 | 21.3% | 17.6% | ||
| Q2 25 | 21.5% | 12.7% | ||
| Q1 25 | 15.5% | 8.7% | ||
| Q4 24 | 22.7% | 22.6% | ||
| Q3 24 | 22.6% | 27.4% | ||
| Q2 24 | 18.1% | -4.6% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 16.9% | 16.2% | ||
| Q2 25 | 17.2% | 11.2% | ||
| Q1 25 | 12.3% | 6.5% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | 25.2% | ||
| Q2 24 | 14.5% | -9.6% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $0.26 | ||
| Q3 25 | $0.72 | $0.17 | ||
| Q2 25 | $0.73 | $0.12 | ||
| Q1 25 | $0.47 | $0.06 | ||
| Q4 24 | $0.69 | $0.40 | ||
| Q3 24 | $0.75 | $0.41 | ||
| Q2 24 | $0.57 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $246.6M | $130.3M |
| Total Assets | — | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $97.5M | ||
| Q3 25 | $54.7M | $94.4M | ||
| Q2 25 | $48.5M | $96.0M | ||
| Q1 25 | $44.8M | $93.2M | ||
| Q4 24 | $44.1M | $101.0M | ||
| Q3 24 | $63.7M | $96.7M | ||
| Q2 24 | $30.6M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $130.3M | ||
| Q3 25 | $274.8M | $115.3M | ||
| Q2 25 | $265.6M | $104.7M | ||
| Q1 25 | $260.8M | $97.1M | ||
| Q4 24 | $257.3M | $92.1M | ||
| Q3 24 | $314.4M | $71.1M | ||
| Q2 24 | $301.0M | $48.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $216.3M | ||
| Q3 25 | $1.2B | $202.9M | ||
| Q2 25 | $1.2B | $194.9M | ||
| Q1 25 | $1.2B | $196.2M | ||
| Q4 24 | $1.2B | $213.3M | ||
| Q3 24 | $1.3B | $220.7M | ||
| Q2 24 | $1.2B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $14.4M | ||
| Q3 25 | $10.7M | $9.7M | ||
| Q2 25 | $-8.4M | $14.1M | ||
| Q1 25 | $-1.8M | $3.6M | ||
| Q4 24 | $24.2M | $15.6M | ||
| Q3 24 | $8.4M | $11.0M | ||
| Q2 24 | $-2.6M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | $14.4M | ||
| Q3 25 | $9.8M | $9.7M | ||
| Q2 25 | $-9.5M | $14.1M | ||
| Q1 25 | $-1.8M | $3.6M | ||
| Q4 24 | $23.4M | $15.6M | ||
| Q3 24 | $8.4M | $11.0M | ||
| Q2 24 | $-2.6M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 19.1% | ||
| Q3 25 | 11.9% | 17.7% | ||
| Q2 25 | -11.7% | 26.8% | ||
| Q1 25 | -2.5% | 7.7% | ||
| Q4 24 | 31.5% | 26.4% | ||
| Q3 24 | 10.7% | 13.7% | ||
| Q2 24 | -3.5% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 1.3% | 0.0% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 1.1% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | 1.10× | ||
| Q2 25 | -0.61× | 2.41× | ||
| Q1 25 | -0.20× | 1.21× | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | 0.54× | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
